Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Change-Receivables" stands at -1.32 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.
Johnson & Johnson's third quarter result of 0.111 Billion USD for the item "Change Receivables" represents an increase of 108.18 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 0.111 Billion USD for the item "Change Receivables" represents an increase of 215.62 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of -1.32 Billion USD for the item "Change Receivables" represents an increase of 13.56 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an decrease of -0.287 Billion United States Dollars compared to the value the year prior.
The 1 year change is -0.287 Billion United States Dollars.
The 3 year change is 0.856 Billion United States Dollars.
The 5 year change is -1.26 Billion United States Dollars.
The 10 year change is -0.561 Billion United States Dollars.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Change Receivables | 905,699,262,464.00 |
![]() | AbbVie Inc - Change Receivables | 399,570,305,024.00 |
![]() | Roche Holding AG - Change Receivables | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Change Receivables | 280,205,508,085.11 |
![]() | Novartis AG - Change Receivables | 255,096,620,580.91 |